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A Personal View of Gene Targeting 
Mario R. Capecchi 
Gene targeting provides the means for creating strains of mice with mutations 
in virtually any gene.1 First, the desired mutation is introduced into a cloned 
copy of the chosen gene by standard recombinant DNA technology. The mu-
tation is then transferred to the genome of a pluripotent mouse emhryo-derived 
stem (ES) cell by means of homologous recombination between tbe exogenous, 
mutated DNA sequence and the cognate DNA sequence in the ES cell duo-
mosome. By microinjection of ES cells containing the transferred mutation 
into blastocysts and by allowing the embryos to come to term in foster moth-
ers, we can generate chimeric mice capable of transmitting the mutation to 
their offspring (germ line chimeras). Finally, interbreeding of heterozygous sib-
lings yields animals homozygous for the desired mutation. Figure 1 outlines the 
steps, from cultured ES cells to chimeric mouse, used to generate mice with 
targeted mutations. 
The power of gene targeting is that the investigator chooses which gene to 
modify and has virtually complete control over the way in which that gene's 
DNA sequence is modified. This technology permits the evaluation of the func-
tions of genes in an intact mammal and the systematic dissection of the most 
complex of biologic processes such as development and learning. Because 
nearly all biologic phenomena are mediated or influenced by genes, this tech-
nology will have an impact on the analysis of all such phenomena in mammals, 
including the study of cancer, immunology, neurobiology, and human genetic 
disease. 
Figure 2 shows a schematic representation of the gene-targeting reaction at 
the DNA level. The uppermost line (X) represents the targeting vector carrying 
sequences of the chosen gene with a precise modification introduced by re-
combinant DNA technology. One point that I wish to stress is that the modi-
fication depicted by the X can be almost any change in the cloned DNA se-
quence-the deletion, addition, or substitution of a single base pair, or the 
deletion, addition, or substitution of thousands of base pairs. Thus, the inves-
tigator has enormous freedom on how to modify the chosen gene. On entering 
the cell nucleus, the targeting vector associates with the cell's homologousre-
combination machinery, searches the entire genome (approximately 3 X 109 
base pairs), finds the cognate sequence in the chromosome, aligns with this 
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Figure 1. Generation of mouse germline chimeras from embryo-derived stem (ES) cells con-
taining a targeted disruption. The first step involves the isolation of a clonal ES cell line 
containing the desired targeted disruption. The second step is to use those cells to generate 
chimeric mice able to transmit the mutant gene to their progeny. To facilitate i~lation of the 
desired progeny, the ES cells and recipient blastocysts are derived from mice with distin-
guishable coat color alleles. This permits the evaluation of the extent of chimerism by visual 
assessment of coat color chimerism and the evaluation of ES cell contribution to the fonna-
rion of the germline by observation of the coat color of chimeric progeny. 
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Figure 2. Diagram of the gene-targeting reaction. Homologous recombination between an 
exogenous mutated copy of the chosen gene and the cognate gene within the host cell chro-
mosome. 
mation with the endogenous chromosomal DNA sequence. As a consequence, 
the specific gene modification created originally in a test tube is transferred to 
the genome of the living celL 
As a corecipient, with Oliver Smithies, of the 1994 Sloan Prize of the Gen-
eral Motors Cancer Research Foundation, I was asked to document our role in 
the development of this gene-targeting technology. The chronology that fol-
lows should be viewed in that light; it is not a review of the field, but rather a 
sketch of the factors that influenced our thinking and some of the highlighrs 
that maintained the momentum of our research effort. 
Our entry into what was going to become the field of gene targeting started 
in 1977. At this time, I was experimenting with the use of extremely small 
glass needles to inject DNA directly into nuclei of living mammalian cells. The 
needles were controlled by hydraulically driven micromanipulators and di-
rected into nuclei with the aid of a microscope. M. Wigler and R. Axel had just 
reported the successful transfer of a herpes simplex virus-thymidine kinase 
gene (HSV-tk) into tk- cells by calcium phosphate coprecipitation.2 Although 
a very important contribution to somatic cell genetics, their procedure was 
not very efficient. Approximately 1 in 1 million cells exposed to the calcium 
phosphate-DNA coprecipitate acquired the exogenous gene in a functional 
form. However, Wigler and Axel could readily identify such rare cells by grow-
ing the treated cells in a medium that killed all cells that did not contain a 
functional tk gene. 
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Using the same experimental paradigm, I asked whether I could introduce 
a functional tk gene into cells by injecting the DNA directly into their nuclei. 
This procedure turned out to be extremely efficient. One in three cells received 
the DNA in a functional form and went on to divide and stably pass that DNA 
on to its daughter cells.3 The high efficiency of microinjection meant that it was 
practical for investigatOrs to use this technology to generate transgenic mice by 
injecting the DNA into one-cell zygotes and allowing the embryos to come to 
term in foster mothers. Indeed, a few years later, microinjection was used by 
Gordon et al.;' Costantini and Lacy,s Brinster et al.,6 Wagner et al./ and 
Wagner et al.8 to generate the first transgenic mice. Generation of transgenic 
animals in this way involves introduction of exogenous DNA segments at un-
predictable locations in the recipient genome, not targeted genetic alterations 
at defined sites. 
To obtain efficient functional transfer of the tk gene into cells, I had to add 
other short viral DNA sequences to the HSV-tk gene. The rationale for doing 
this experiment in the first place was simple. Mammalian viruses have evolved 
to propagate themselves efficiently within mammalian cells. It thus seemed pos-
sible that their genome contained sequences that enhanced their ability to es-
tabiish themselves within the competitive mammalian host genome. The first 
viral genome in which I chose to look for such sequences was SV40, a simian, 
lytic DNA virus. Indeed, I was able to identify a DNA sequence located near 
the SV40 origin of DNA replication, which when coupled to the HSV-tk gene 
increased its efficiency in conferring a tk+ phenotype on the tk- recipient cells 
by a factor of more than 100. For a number of reasons, I did not believe that 
this enhancement was the result of HSV-tk plasmid replication within the re-
cipient cells. First, the cells I used for these experiments were derived from a 
mouse, and SV40 is not able to replicate in murine cells. Second, the enhance-
ment of transfonning tk- cells into te cells was not dependent on including, 
in rhe HSV-tk plasmid, SV40 sequences that encoded the large T-antigen, 
which is required for SV40 replication. Southern transfer analysis of the tk+ 
celis showed that the newly added HSV-tk DNA sequences were integrated 
into the host genome. I conduded that this efficiency-enhancing sequence was 
either increasing the frequency with which the exogenous DNA integrated into 
the host genome, or increasing the probability that the tk gene, once integrated 
into a host genome, would be functional. 3 In collaboration with Luciw, Bishop, 
and Varmus, we showed that the avian sarcoma virus (ASV) also contained, 
within its long terminal repeats, sequences that enhanced HSVtk-mediated 
transformation.3,9 This was of particular interest because the lifestyles of SV40 
and the ASV retrovirus were so different, yet both possessed sequences within 
their genome that functioned similarly to enhance fonnation of stable tk+ 
transformants. These experiments were carried out before the concept of so-
called enhancers and in fact contributed to their definition.1O 
The observation that I found most fascinating from these early microinjec-
tion experiments was that when multiple copies of the tk plasmid were injected 
into a ceU, although they were integrated into random locations within the 
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host chromosomes, they were always present in head-to-tail concatemers. Such 
highly ordered concatemers could be generated in two ways: (1) by replication 
(e.g., a rolling circle mechanism), or (2) by homologous recombination. We 
were able to prove that the concatemers were generated by homologous re-
combination. l1 The significance of this observation was its demonstration that 
mammalian cells contained an efficient machinery for mediating homologous 
recombination. 
This was a startling discovery because it was always assumed that the func-
tion of homologous recombination in all organisms was to ensure broad dis-
semination of the parental genetic traits to their offspring by shuffling these 
traits in the germ cells. Finding evidence for the activity of this machinery in 
mouse fibroblast cells implied that all cells, somatic and germ cells, were capa-
ble of mediating homologous recombination. We suspected that the homolo-
gous recombination machinery in somatic cells was very efficient because I 
could inject more than 100 tk plasmid molecules per cell and they were all 
incorporated into a single, ordered, head-to-tail concatemer. I realized imme-
diately that if we could harness this machinery to carry out homologous re-
combination between a newly introduced DNA molecule of our choice and 
the same DNA sequence in the cell's chromosome, we would have the ability 
to specifically mutate or modify virtually any gene in the cell. 
I first talked publicly about the results from the microinjection experi-
ments at a NATO-sponsored course in Estaril, Portugal in the spring of 1978. 
Frank Ruddle was also an instructor in that course, and he became a champion 
and rapid disseminator of our results. A commonly held misconception is that 
the motivation for our laboratory to pursue gene targeting in mammalian cells 
was the success of Fink's group in achieving gene targeting in yeast.12 This is 
not the case. We were aware a year earlier that mammalian cells possessed 
the enzymatic machinery for efficient mediation of homologous recombination 
between newly introduced DNA molecules. It was this awareness that pro-
vided us with the incentive to pursue gene targeting in mammalian cells. 
We spent the next few years becoming familiar with this machinery by 
studying recombination between cointroduced DNA substrates. From these 
experiments, it became evident that this enzymatic machinery could mediate a 
wide spectrum of reactions, including conservative and nonconservative ho-
mologous recombination. Both reciprocal and nonreciprocal recombination 
events were apparent among the products of recombination, although we ob-
served a distinct bias towards mediating nonreciprocal reactions.13,14 We found 
that a cell's ability to carry out homologous recombination depends on a cell's 
position in the cell cycle, showing a peak of activity in early S phase.1s Kinetic 
analysis of homologous recombination between cointroduced DNA molecules 
indicated that the reaction occurred very rapidly, within 30 minutes after the 
DNA was introduced into the nucleus.13 Later, the DNA molecules become 
refractory to participation in homologous recombination. Exclusion from par-
ticipation in homologous recombination coincides with the time at which the 
newly introduced DNA is packaged into chromatin. These studies suggested 
that the cdh:dar emymatic machinery could be exploited to mediate homolo-
gous mcombination between newly added exogenous DNA sequences and 
chromosomal sequences. 
In 1980, I submitted a National Institutes of Health (NIH) grant proposal 
outlining experiments intended to test the feasibility of gene targeting in mam-
malian cells. The proposal elicited an interesting response. In the opinion of 
the peer reviewers, the probability that the newly introduced DNA would ever 
nnd its matching sequence within the host genome was vanishingly small. 
Aware that the frequency of gene-targeting events could be very low, the ex-
perimental paradigm that we proposed allowed for the selection of cells con-
taining the desired recombinant product. One such paradigm (see Figure 3) 
im"olved, first, random introduction of a defective copy of a gene, such as HSV-
tk or ned, into (he host chromosome. This was to be followed by introduction 
into those recipient cells of plasmids containing the gene with a different mu-
tation and then selection for those cells that had generated, by homologous 
recombination, a functional gene from the two defective parts. This particular 
paradigm met with skepticism in some circles because it was viewed that the 
target in the chromosome was artificial (i.e., composed of a randomly intro-
duced DNA sequence). I always viewed this skepticism with amusement be-
cause the homologous recombination machinery does not appear to discrimi-
nate with respect to DNA sequence content. What appeared to be crucial to 
this machinery was merely that the sequences between the target and incoming 
DNA match perfectly. 
---~-
~ 3. R~ a functional gene by homologous recombination from two defective 
copieS of the gene, oat lOcated in the host chromosome, and the second newly introduced 
imo the recipient eel. 
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Despite rejection of the NIH proposal and skepticism of some, we pursued 
experiments using the proposed design. Because the experimental approach 
allowed us to select for rare recombination events in cell culture, we could do 
many more experiments and thereby establish the parameters that influenced 
the gene-targeting frequency. These experiments revealed some unexpected 
features. For example, the frequency of gene targeting was not dependent on 
the number of targeting vectors introduced into the recipient cell, nor on the 
number of targets present in the host genome.14,16 This is in contrast to what is 
observed in yeast, in which the targeting frequency is proportional to the num-
ber of target sequences in the genome.17,18 In yeast, targeting into the ribosomal 
RNA genes, which are present at 140 copies per genome, is 100 to 200 times 
more frequent than targeting into the single copy leu-2 gene. 
Gene targeting in yeast and mammalian cells differs in another important 
respect. The frequency depends more on the extent of homology between the 
exogenous and chromosomal sequences in mammalian cells than it does in 
yeast. In yeast, this dependence is linear, but in mammalian cells it appears to 
be exponentiaI.19,lO Whereas the efficiency of the recombination system in yeast 
appears to saturate with a few hundred base pairs of perfect homology, in 
mammalian cells the system does not saturate until approximately 15 kb of 
sequence homology exists between the added DNA and the target locus. These 
differences in the properties of the homologous recombination machinery be-
tween yeast and mammalian cells may reflect differences in their genome orga-
nization. For example, the yeast genome has far fewer repetitive DNA se-
quences than the mammalian genome. In mammalian somatic cells, although 
the homologous recombination machinery is an important component of the 
DNA repair machinery, it is equally important that this machinery not inadver-
tently mediate recombination between repetitive DNA sequences. Such recom-
bination would result in instability of the mammalian genome and loss of criti-
cal genetic information. The dependency of homologous recombination ma-
chinery in mammalian cells on long stretches of homologous DNA sequences 
greatly reduces the probability of homologous recombination between repeti-
tive DNA sequences, without impairing its ability to participate in DNA repair. 
By 1984, we were confident that it was feasible to do gene targeting in 
cultured mammalian cells, and we presented our work at a memorable sympo-
sium on homologous recombination held at the Cold Spring Harbor Labora-
tory.21 The next question we pursued was whether gene targeting could be 
extended to a whole animal (i.e., the mouse). Because of the low frequency of 
targeting events in mammalian cells, it was dear that doing the experiments 
directly in mouse zygotes would not be practical: Rather, targeting events had 
to be identified first in cultured cells to allow purification of a clonal cell line 
containing the desired gene disruption; these cells in turn could be used to 
generate mice capable of transmitting the mutation in their germline, We were 
familiar with the frustrations associated with previous attempts to obtain genu-
line chimeras using embryonal carcinoma (EC) cells. 
However, in the summer of 1984, I heard at a Gordon Research Confer-
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ence a discussion of EK cells, which appeared to be much more promising in 
rheir potential for contributing to the gennline. EK cells, which were developed 
in Martin Evans' laboratory in Cambridge, England, differed from EC cells in 
that they were obtained from the early mouse embryo22 rather than from a 
mouse tumor. In the winter of 1985, I arranged to spend a week in Martin 
Evans' laboratory to learn how to culture and manipulate mouse EK cells. It 
was just before Christmas, a marvelous time to be in Cambridge, England. 
While I was there, Martin Evans confided to me that the only other molecular 
biologist who had shown any interest in EK cells, now called ES cel/s, was 
Oliver Smithies. I believe that most investigators showed little interest in ES 
cells because they thought of the mouse as a system for expressing exogenous 
genes. There were only modest advantages to using ES cells as a vehicle to 
generate such transgenic mice, and those advantages were not enough to coun-
terbalance the lower efficiency of obtaining gennline transmission of the for-
eign DNA by the ES cell route. However, to pursue gene targeting to generate 
mutations in the mouse, we had no choice but to take the ES cell route. In 
short, at that time there were few attractive experiments that could be done 
with ES cells. 
In 1986, our total effort was switched to ES cells. We also decided to 
use electroporation rather than micro injection as a means of introducing the 
targeting vector into cells. Although microinjection was orders of magnitude 
more efficient than electroporation as a means of introducing DNA into cells, 
injections had to be done one cell at a time, and I was getting tired of doing 
microinjections. With electroporation, 108 cells could be manipulated in a sin-
gle experiment. I also thought that if electroporation worked, the gene-
targeting technology would be more readily transferable to other investigators. 
The gene that we chose to disrupt in ES cells was hprt, because it provided 
us the luxury of being able to select directly for cells containing the disrupted 
gene. Because the hprt gene is located on the X chromosome and the ES cells 
were derived from a male mouse, only a single locus had to be disrupted to 
yield hprt- cell lines. The strategy that we employed was to use a neomycin-
resistance gene (ned) to disrupt the hprt genomic sequences and then to select 
for cells resistant to both G418, a neomycin analogue, and 6-thioguanine (6-
TG), a drug toxic to cells with a functional hprt gene. All such selected cell lines 
had lost hprt enzymatic activity as a result of targeted disruption of the hprt 
locus. These experiments showed that ES cells were good recipients, able to 
mediate homologous recombination, and that the selection protocols required 
to identify cell lines containing the targeted disruption did not alter their plu-
ripotent state in culture. 
This system also provided a good experimental model for exploration of 
the parameters affecting the efficiency of gene targeting.19 We compared two 
c.lasses of targeting vectors, sequence replacement vectors, and sequence inser-
tion vectors, and showed that the targeting efficiency of both classes of vectors 
was strongly dependent on the extent of homology between the exogenous 
and endogenous DNA sequences. We also outlined a number of enrichment 
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strategies, including promoter trapping, for extending the technology to mod-
ify genes whose disruption does not provide a cell-selectable phenotype. I be-
lieve that this study played a pivotal role in the development of me field by 
encouraging other investigators to begin to use gene targeting as a means for 
determining the function of genes in mammals. 
Although mammalian cells have the machinery to direct the newly intro-
duced DNA to its endogenous target, we found that the targeting vector is 
more often inserted into a random site within the host genome by nonhomol-
ogous recombination. The ratio of homologous to nonhomologous recombi-
nation events is approximately 1 to 1,000. Because disruption of most genes is 
not expected to produce a phenotype selectable at the cell level, an investigaror 
seeking a specific disruption must therefore either screen through many colo-
nies of cells to identify the rare colony that contains the desired targeting event 
or use selections that enrich for cells containing the targeting event. 
Late in 1986 I conceived of a very general strategy to enrich for cells in 
which the targeting event had occurred. It was based on key observations made 
during our studies of recombination events involving exogenous DNA in mam-
malian cells, namely that incorporation of DNA segments at random nonho-
mologous sites involved insertions of a linearized vector in its entirety through 
its ends, whereas recombination at a homologous target site, of a replacement 
type vector, involved crossover events occurring only through homologous se-
quences in the vector. The strategy based on these observations and known as 
positive-negative selection uses two components (Figure 4). One component is 
referred to as a positive selectable gene, neor, used as a marker to select for 
cells that have incorporated the targeting vector anywhere in the recipient cell 
genome (i.e., at the target site by homologous recombination or at random sites 
by nonhomologous recombination). The second component is called a negative 
selectable gene and is located at one end of the linearized targeting vector and 
used to select against cells containing random insertion of the targeting vector. 
The net effect is to enrich for cells in which the desired homologous targeting 
event has occurred. 
The strength of this enrichment procedure is that it is independent of the 
function of the gene and succeeds whether or not the gene is expressed in the 
recipient ES cells.23 Positive-negative selection is now the most frequently used 
procedure to enrich for cells containing targeting events. We evaluated several 
negative selectable genes, including xgpt, hprt, and the diphtheria-toxin gene, 
and finally settled on HSV-tk. The origin of the idea for positive-negative se-
lection was not very romantic and involved purely deductive reasoning. En-
richment for cells containing the targeting event could be achieved either by 
direct selection for cells containing the targeting event or by elimination of 
cells that contained random insertions of the targeting vector. This truism, 
coupled with an understanding of how information is transferred between an 
exogenous and an endogenous DNA sequence by homologous and nonhomol-
ogous recombination, naturally led to the concept of positive-negative 
selection. 
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Figure 4. The positive-negative selection procedure used to enrich for ES cells containing a 
targeted disruption in gene X. (A) A gene X sequence replacement vector, which contains an 
insertion of the nro' gene in an exon of gene X and a linked HSV-tk gene, is shown pairing 
with the chromosomal copy of gene X. Homologous recombination between the targeting 
vector and genomic X DNA results in the disruption of one copy of genomic gene X and the 
loss of rhe vector's HSV·tk sequences. Cells resulting from such an event will be X- neo'+ 
and HSV-!k- and will be resistant to both G418 and ganciclovir. (B) Integration at a random, 
nonhomologous site. Because nonhomologous insertion of exogenous DNA into the chro-
mosome occurs through the ends of the linearized DN A, the HSV ·tk gene will remain linked 
to the ned gene. Cells derived from this type of event will be X+, neoff and HSV-tk+ and 
therefore resistant to G418 but sensitive to g;<ncidovir. Ganciclovir is a nucleoside analogue 
th.1t specifically kills cells containing a functional HSV·tk gene but is not toxic to cells con-
taining the cellular tlr. gene. 
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The use of gene targeting to evaluate the functions of genes in the living 
mouse is now a routine procedure. It is very gratifying to be able to pick up 
almost any major journal in the biologic sciences and find the description of 
yet another so-called gene knockout mouse. In the past 5 years, the in vivo 
functions of well over 250 genes have been determined. It is relatively easy to 
project where gene-targeting technology will go in the near future. It will con-
tinue to serve as the way to determine the roles of individual genes in mamma-
lian biology. This will be accomplished by the generation of null mutations 
knocking out the genes of interest. Those investigators who desire deeper in-
sights will generate an allelic series of mutations in a chosen gene to evaluate 
the effects of partialloss-of-function and gain-of-function mutations. To per-
mit the evaluation of potential multiple roles of a gene in multiple tissues, gene 
targeting will be used to engineer tissue-specific gene disruptions using the cre / 
10xP system.24 Further, technology should soon become available that will al-
low the investigator to tum chosen genes on or off in the adult or during any 
phase of mouse development. Finally, because most biologic processes are me-
diated by interactions among a number of genes, such phenomena will be stud-
ied by combination of multiple targeted mutations in a single mouse. There is 
no question that the mouse is a very complex organism. However, the broad 
range of genetic manipulations now available through gene targeting should 
provide a means for us to begin deciphering even the most complex of biologic 
processes such as development and learning. 
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